51˶

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

As an FDA-mandated rule goes into effect , the American Cancer Society has an explainer on what the rule means for patients and providers.

Analysis of another dataset of patients treated with CAR T-cell therapy showed a 5.2% within 1 year. (Epic Research)

A survivor of advanced breast cancer has turned her experience into a . (Cedars-Sinai)

Results of a small clinical study suggested that piano lessons for cancer patients might help alleviate (U.S. News & World Report)

Johnson & Johnson announced discontinuation of a phase III trial of intravesical extended-release gemcitabine (TAR-200) plus cetrelimab versus chemoradiation for after an interim analysis showed no difference in bladder-intact event-free survival.

Merck announced that a phase III trial of perioperative pembrolizumab (Keytruda) combined with adjuvant radiation therapy (with or without chemotherapy) for met the primary endpoint of improved event-free survival versus adjuvant radiation therapy (with or without chemotherapy) alone.

Pfizer announced that a phase III trial of talazoparib (Talzenna) plus enzalutamide (Xtandi) met the primary endpoint of in metastatic castration-resistant prostate cancer compared with enzalutamide alone.

Commonly used breast cancer therapies -- including chemotherapy, radiation, and surgery -- increase production of . (UCLA Health Jonsson Comprehensive Cancer Center, Journal of the National Cancer Institute)

A may be able to detect and inhibit tumor recurrence. (Advanced Science)

Should increased reliance on industry be cause for concern? (UNC Lineberger Comprehensive Cancer Center, Journal of Clinical Oncology)

A husband-and-wife cancer research team in Iran over published research involving cancer cell lines that allegedly were not available through the national cell bank. (Retraction Watch)

A blood test for reliably predicted response to treatment and prognosis in men with metastatic hormone-sensitive prostate cancer. (USC Keck School of Medicine, JAMA Network Open)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 51˶ in 2007.